Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 12/20 | 0.51 |
| ▸ | CKS1B | P61024 | 2/20 | 0.48 |
| ▸ | SKP1 | P63208 | 2/20 | 0.48 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24851765 | 1.00 | GBA1 (0.51) | GBA1CKS1BSKP1SKP2MAP4K4 | |
| SCHEMBL30162196 | 0.99 | GBA1 (0.50) | GBA1CKS1BSKP1SKP2MAP4K4 | |
| SCHEMBL18162447 | 0.99 | GBA1 (0.50) | GBA1CKS1BSKP1SKP2MAP4K4 | |
| SCHEMBL24851167 | 0.99 | GBA1 (0.50) | GBA1CKS1BSKP1SKP2MAP4K4 | |
| SCHEMBL30161992 | 0.98 | CKS1B (0.52) | GBA1CKS1BSKP1SKP2MAP4K4 | |
| SCHEMBL24851472 | 0.98 | CKS1B (0.52) | GBA1CKS1BSKP1SKP2MAP4K4 | |
| SCHEMBL24851770 | 0.98 | CKS1B (0.52) | GBA1CKS1BSKP1SKP2MAP4K4 | |
| SCHEMBL30162245 | 0.96 | CKS1B (0.49) | GBA1CKS1BSKP1SKP2MAP4K4 | |
| SCHEMBL24851452 | 0.96 | CKS1B (0.49) | GBA1CKS1BSKP1SKP2MAP4K4 | |
| SCHEMBL9669980 | 0.91 | GBA1 (0.56) | GBA1CKS1BSKP1SKP2MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3283472-B1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | UNIV INDIANA RES & TECH CORP (US) | 2021-04-14 | — | — | EP | disclosed |
| US-10273228-B2 | Hepatitis B viral assembly effectors | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-04-30 | — | — | US | disclosed |
| US-20180099952-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-04-12 | — | — | US | disclosed |
| US-20180099952-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-04-12 | — | — | US | disclosed |
| EP-3283472-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | Indiana University Research&Technology Corporation (US) | 2018-02-21 | — | — | EP | disclosed |
| WO-2016168619-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-10-20 | — | — | WO | disclosed |
| WO-2016168619-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099952-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | HAVCR2, MAVS, HCCS | GBA1 1585/4885CKS1B 811/4885SKP1 4065/4885 |
| US-10273228-B2 | Hepatitis B viral assembly effectors | HAVCR2, MAVS, HCCS | GBA1 1585/4885CKS1B 811/4885SKP1 4065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.